New Drug for Chronic Myeloid Leukemia Might Stimulate the Market
The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerabilit...
Saved in:
| Published in | Clinical cancer research Vol. 27; no. 1; pp. 3 - 4 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | English |
| Published |
United States
01.01.2021
|
| Online Access | Get full text |
Cover
Loading…
| Summary: | The evolution of treatment options over the past 20 years has provided for a normal life expectancy for most patients with chronic myeloid leukemia. Currently approved tyrosine kinase inhibitors mainly differ in potency and side effect profile. Flumatinib goes for deep responses and good tolerability.
See related article by Zhang et al., p. 70 |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Commentary-3 content type line 23 |
| ISSN: | 1078-0432 1557-3265 1557-3265 |
| DOI: | 10.1158/1078-0432.CCR-20-3684 |